CA2309324A1 - Gene qui amorce une activite de proliferation selective - Google Patents

Gene qui amorce une activite de proliferation selective Download PDF

Info

Publication number: CA2309324A1
Authority: CA; Canada
Prior art keywords: cells; gcrtmr; cell; vector; receptor
Prior art date: 2000-05-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2309324

Other languages

English (en)

Inventor

Keiya Ozawa

Katsuhisa Itoh

Tsuneaki Sakata

Yasuji Ueda

Mamoru Hasegawa

Takeyuki Nagashima

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Dnavec Research Inc

Original Assignee

Dnavec Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-23

Filing date

2000-05-23

Publication date

2001-11-23

2000-05-23 Application filed by Dnavec Research Inc filed Critical Dnavec Research Inc

2000-05-23 Priority to CA 2309324 priority Critical patent/CA2309324A1/fr

2001-11-23 Publication of CA2309324A1 publication Critical patent/CA2309324A1/fr

Status Abandoned legal-status Critical Current

Links

108090000623 proteins and genes Proteins 0.000 title claims abstract description 50
230000000694 effects Effects 0.000 title claims abstract description 17
230000035755 proliferation Effects 0.000 title claims abstract description 17
108020001507 fusion proteins Proteins 0.000 claims abstract description 28
102000037865 fusion proteins Human genes 0.000 claims abstract description 27
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims abstract description 25
229940011871 estrogen Drugs 0.000 claims abstract description 24
239000000262 estrogen Substances 0.000 claims abstract description 24
108010038795 estrogen receptors Proteins 0.000 claims abstract description 24
102000015694 estrogen receptors Human genes 0.000 claims abstract description 23
229960001603 tamoxifen Drugs 0.000 claims abstract description 13
239000002207 metabolite Substances 0.000 claims abstract description 12
239000013598 vector Substances 0.000 claims description 44
108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 claims description 30
102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 claims description 29
108010057085 cytokine receptors Proteins 0.000 claims description 13
102000003675 cytokine receptors Human genes 0.000 claims description 13
230000002062 proliferating effect Effects 0.000 claims description 7
238000000034 method Methods 0.000 claims description 6
102000005969 steroid hormone receptors Human genes 0.000 claims description 4
108020003113 steroid hormone receptors Proteins 0.000 claims description 4
108020001756 ligand binding domains Proteins 0.000 claims description 2
108020004414 DNA Proteins 0.000 claims 3
239000003446 ligand Substances 0.000 abstract description 4
230000004936 stimulating effect Effects 0.000 abstract description 4
230000003321 amplification Effects 0.000 abstract description 2
238000003199 nucleic acid amplification method Methods 0.000 abstract description 2
210000004027 cell Anatomy 0.000 description 124
102100039064 Interleukin-3 Human genes 0.000 description 24
108010002386 Interleukin-3 Proteins 0.000 description 23
229940076264 interleukin-3 Drugs 0.000 description 23
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 20
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 20
241001529936 Murinae Species 0.000 description 20
210000001185 bone marrow Anatomy 0.000 description 20
230000012010 growth Effects 0.000 description 20
210000003958 hematopoietic stem cell Anatomy 0.000 description 20
239000012634 fragment Substances 0.000 description 17
239000006228 supernatant Substances 0.000 description 17
238000010361 transduction Methods 0.000 description 17
230000026683 transduction Effects 0.000 description 17
239000002299 complementary DNA Substances 0.000 description 14
230000004044 response Effects 0.000 description 14
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
102000039446 nucleic acids Human genes 0.000 description 12
108020004707 nucleic acids Proteins 0.000 description 12
150000007523 nucleic acids Chemical class 0.000 description 12
230000003612 virological effect Effects 0.000 description 12
230000001419 dependent effect Effects 0.000 description 10
238000001415 gene therapy Methods 0.000 description 10
238000003556 assay Methods 0.000 description 9
230000027455 binding Effects 0.000 description 9
WNKZOJNKBOBRAY-UHFFFAOYSA-N cdba Chemical compound O=CC1=CC=CC=C1.O1C(C(C2O)O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC(C(O)C2O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC2C(O)C(O)C1OC2COC WNKZOJNKBOBRAY-UHFFFAOYSA-N 0.000 description 9
230000004927 fusion Effects 0.000 description 9
230000001177 retroviral effect Effects 0.000 description 9
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 8
239000012091 fetal bovine serum Substances 0.000 description 8
108010048367 enhanced green fluorescent protein Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
238000000246 agarose gel electrophoresis Methods 0.000 description 6
238000001516 cell proliferation assay Methods 0.000 description 6
238000003752 polymerase chain reaction Methods 0.000 description 6
241001430294 unidentified retrovirus Species 0.000 description 6
DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 5
108090000695 Cytokines Proteins 0.000 description 5
102100037362 Fibronectin Human genes 0.000 description 5
108010067306 Fibronectins Proteins 0.000 description 5
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
102100034195 Thrombopoietin Human genes 0.000 description 5
210000002798 bone marrow cell Anatomy 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
229960002949 fluorouracil Drugs 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
210000000130 stem cell Anatomy 0.000 description 5
238000001890 transfection Methods 0.000 description 5
210000000601 blood cell Anatomy 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000007774 longterm Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
239000004475 Arginine Substances 0.000 description 3
241000710188 Encephalomyocarditis virus Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
239000002033 PVDF binder Substances 0.000 description 3
230000004913 activation Effects 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
230000003021 clonogenic effect Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229920002981 polyvinylidene fluoride Polymers 0.000 description 3
238000011160 research Methods 0.000 description 3
108010056030 retronectin Proteins 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
210000000689 upper leg Anatomy 0.000 description 3
APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000725101 Clea Species 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
241000282567 Macaca fascicularis Species 0.000 description 2
101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
108700019146 Transgenes Proteins 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000003636 conditioned culture medium Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
102000052611 human IL6 Human genes 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
238000002826 magnetic-activated cell sorting Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
229960005322 streptomycin Drugs 0.000 description 2
238000004114 suspension culture Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
238000000035 BCA protein assay Methods 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
101710173353 Cytotoxicity-associated immunodominant antigen Proteins 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 1
101710177504 Kit ligand Proteins 0.000 description 1
102100020880 Kit ligand Human genes 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
238000000719 MTS assay Methods 0.000 description 1
231100000070 MTS assay Toxicity 0.000 description 1
101000882586 Mus musculus Estrogen receptor Proteins 0.000 description 1
101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
101000882573 Rattus norvegicus Estrogen receptor Proteins 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
101000716735 Rattus norvegicus Kit ligand Proteins 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
150000001483 arginine derivatives Chemical class 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000002737 cell proliferation kit Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
108700010039 chimeric receptor Proteins 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000005757 colony formation Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000004163 cytometry Methods 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000010432 diamond Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
102000044890 human EPO Human genes 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
238000007898 magnetic cell sorting Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000011325 microbead Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000047 product Substances 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000002303 tibia Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
High Energy & Nuclear Physics (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

CA 2309324 2000-05-23 2000-05-23 Gene qui amorce une activite de proliferation selective Abandoned CA2309324A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2309324 CA2309324A1 (fr)	2000-05-23	2000-05-23	Gene qui amorce une activite de proliferation selective

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2309324 CA2309324A1 (fr)	2000-05-23	2000-05-23	Gene qui amorce une activite de proliferation selective

Publications (1)

Publication Number	Publication Date
CA2309324A1 true CA2309324A1 (fr)	2001-11-23

Family

ID=4166230

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2309324 Abandoned CA2309324A1 (fr)	2000-05-23	2000-05-23	Gene qui amorce une activite de proliferation selective

Country Status (1)

Country	Link
CA (1)	CA2309324A1 (fr)

2000
- 2000-05-23 CA CA 2309324 patent/CA2309324A1/fr not_active Abandoned

Legal Events

Date	Code	Title	Description
2005-04-22	EEER	Examination request
2009-05-25	FZDE	Dead

Publication	Publication Date	Title
KR100353115B1 (ko)	2003-01-06	레트로바이러스를사용한표적세포내로의유전자도입방법
US8889419B2 (en)	2014-11-18	Methods for enhanced virus-mediated DNA transfer using molecules with virus- and cell-binding domains
JP5553989B2 (ja)	2014-07-23	ウィルスベクターを使用した標的化遺伝子送達方法
US20030077249A1 (en)	2003-04-24	Cell activation process and reagents therefor
WO1993014188A1 (fr)	1993-07-22	Virus cible
US20140004089A1 (en)	2014-01-02	Chimeric glycoproteins and pseudotyped lentiviral vectors
WO1997011604A9 (fr)	1997-05-22	Procedes pour ameliorer le transfert d'adn par mediation virale, en utilisant des molecules avec des domaines permettant une fixation sur le virus et sur la cellule
Maurice et al.	1999	Efficient Gene Delivery to Quiescent Interleukin-2 (IL-2)–Dependent Cells by Murine Leukemia Virus-Derived Vectors Harboring IL-2 Chimeric Envelopes Glycoproteins
Xu et al.	1999	A selective amplifier gene for tamoxifen‐inducible expansion of hematopoietic cells
JP2002526083A (ja)	2002-08-20	ポリヌクレオチド構築物およびその使用
US6033907A (en)	2000-03-07	Enhanced virus-mediated DNA transfer
US7083979B1 (en)	2006-08-01	Methods for enhanced retroviral-mediated gene transfer
AU721121B2 (en)	2000-06-22	Inactivation of HIV co-receptors as therapy for HIV infection
WO2000078987A1 (fr)	2000-12-28	Vecteur d'expression de deux genes etrangers
CA2309324A1 (fr)	2001-11-23	Gene qui amorce une activite de proliferation selective
US20030166161A1 (en)	2003-09-04	Gene that imparts selective proliferative activity
EP0995802B1 (fr)	2009-12-23	Procédé pour l'apport des acides nucléiques dans les cellules in vitro ou ex vivo
Nagashima et al.	2003	New selective amplifier genes containing c-Mpl for hematopoietic cell expansion
KR100478430B1 (ko)	2005-07-18	선택적증식성을부여하는유전자
Verhoeyen et al.	2008	Production of lentiviruses displaying “early-acting” cytokines for selective gene transfer into hematopoietic stem cells
TW585909B (en)	2004-05-01	Method for gene transfer into target cells with retrovirus
Hamada et al.	1991	A new method of gene transfer into hematopoietic progenitors using liquid culture with interleukin-3 and interleukin-6
Harboring	1999	Efficient Gene Delivery to Quiescent Interleukin-2 (IL-2)
JP2002325595A (ja)	2002-11-12	レトロウイルスによる標的細胞への遺伝子導入方法